Abstract Library

#4419 Real-world outcomes in patients with gastroenteropancreatic neuroendocrine neoplasms at a cancer centre in a middle-income country

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare tumours that are increasing in prevalence. However, the epidemiology of GEP-NENs in Latin America is not well understood.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, middle-income countries, epidemiology,

#4359 Treatment response and survival in 163 metastatic colorectal neuroendocrine carcinomas: A prospective cohort from the Nordic NEC registry

Introduction: Colorectal neuroendocrine carcinoma (CR-NEC) is a rare and aggressive disease. Most cases are metastatic at diagnosis and palliative chemotherapy is the only systemic treatment option.

Conference:

Presenting Author: Morken S

Authors: Morken S, Langer S, Knigge U, Hjortland G, Sundlöv A,

Keywords: neuroendocrine carcinoma, NEC, colorectal, chemotherapy,

#3793 Decellularised pancreas explants as a novel 3D model for pancreatic neuroendocrine tumors (PNETs) biomarker discovery

Introduction: The lack of preclinical models of pancreatic neuroendocrine tumors (pNETs) challenges advancement in biomarker discovery. Culturing cancer cells in their native tissue enables the study of complex tumor cell-ECM interactions, products of which could be utilised as disease biomarkers.

Conference:

Presenting Author: Ney A

Authors: Ney A, Al-Akkad W, Sedlak E, Garcia-Sampedro A, Hall A,

Keywords: Disease model, Tumor microenvironment, Biomarker discovery, Pancreatic NET,

#3571 A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,

#3355 Clinicopathologic impact of peptide hormonal expression in rectal neuroendocrine tumor

Introduction: Although numerous types of neuroendocrine cells constitute GEP-NETs, the clinical behaviours and prognostic implications of multiple peptide hormonal expression have not been comprehensively evaluated in rectal NETs.

Conference:

Presenting Author:

Authors: Kim J, Yang D, Yoo C, Park I, Ryoo B,

Keywords: rectum, neuroendocrine tumor, hormone, serotonin, somatostatin, prognosis,